A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma

News
Video

William Harris, MD, presents the study design and rationale for HCRN GI15-225, an open-label, single-arm multicenter, pilot study exploring whether using immunotherapy drugs in combination with locoregional therapies for patients with non-metastatic HCC is safe and beneficial, using pembrolizumab every 3 weeks starting 1 week before initial Y90 radioembolization.

Related Videos
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma
Video 16 - "Trajectory of Evolving HCC Treatment Landscape"
Video 15 - "REGONEXT Study: Driving Second-line HCC Treatment Strategy"
Video 12 - "CARES-310 Trial: Impressions and Clinical Impact on HCC Treatment Landscape"
Related Content
John D. Gordan, MD, PhD

ASCO Updates Advanced HCC Treatment Guideline

April 29th 2024
Article
Etienne Garin, MD, PhD

Personalized Dosimetry With Y-90 Glass Microspheres Shows Positive Activity in HCC

April 17th 2024
Article
Michael Iglesia, MD, PhD

Iglesia Spotlights the Current Complexities of Treatment Sequencing in Advanced HCC

April 5th 2024
Article
Rachna T. Shroff, MD, MS, FASCO

ASCO GI Updates Provide Window Into Evolving HCC Treatment Paradigm

March 28th 2024
Article